

~~--28.~~ <sup>1</sup> A sustained-release microparticle comprising:  
risperidone, or a pharmaceutically acceptable acid addition salt thereof, in crystalline  
form; and  
a biodegradable and biocompatible polymeric matrix.

<sup>2</sup>  
~~29.~~ The sustained-release microparticle according to claim ~~28~~ <sup>1</sup>, wherein said polymeric  
matrix comprises a polymer selected from the group consisting of poly(lactic) acid,  
poly(glycolic) acid, copolymers of the foregoing, and polyorthoesters.

<sup>3</sup>  
~~30.~~ A sustained-release microparticle produced by including risperidone, or a  
pharmaceutically acceptable acid addition salt thereof, in the form of crystals into a  
biodegradable and biocompatible polymer selected from the group consisting of poly(lactic)  
acid, poly(glycolic) acid, copolymers of the foregoing, and polyorthoesters.--

*In the Abstract:*

Please delete the Abstract of the Disclosure as it appears on pages 46 and 47 of the  
application as filed herewith, and substitute therefor the Abstract attached hereto on a separate  
sheet.

**Remarks**

The above-captioned continuation application has been filed in order to request that an  
interference be declared with the U.S. national phase application of PCT/JP93/01673 that  
designated the United States (see Request for Interference Under 37 C.F.R. § 1.604 filed  
herewith). To facilitate processing by the PTO, it is requested that the above-captioned  
application be assigned to the same Examiner and Art Unit as the U.S. national phase  
application of PCT/JP93/01673.

0880221 19280880


Upon entry of the foregoing amendment, claims 28-30 are pending in the application, with claims 28 and 30 being the independent claims. Claims 1-27 are canceled without prejudice to or disclaimer of the subject matter therein. New claims 28-30 are added. These changes are believed to introduce no new matter, and their entry is respectfully requested. In this regard, the Examiner is referred to, for example, page 15, line 28 and page 20, line 26 of the above-referenced application that discloses use of an active agent in crystalline form, and page 25, lines 14-22 (Example 1) that discloses a method for producing risperidone in crystalline form.

### *Conclusion*

Prompt and favorable consideration of this Preliminary Amendment is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Andrea G. Reister  
Attorney for Applicants  
Registration No. 36,253

Date: February 28, 1997

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005  
(202) 371-2600

PAUSERS\AREISTER\1611\0510002.PAM  
SLF\AGR:daw

08808261.022897